Characterization of PPAR dual ligand MCC-555 in AOM-induced colorectal tumorigenesis

Experimental and Toxicologic Pathology

Volumn 65, Issue 6, 2013, Pages 919-924

  Imchen, Temjenmongla ^a   Manasse, Jorden ^a   Min, Kyung Won ^a   Baek, Seung Joon ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Aberrant crypt foci; Azoxymethane; Colon cancer; MCC 555; PPAR ligand

Indexed keywords

AZOXYMETHANE; MUCIN 2; NETOGLITAZONE;

ABERRANT CRYPT FOCUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CHEMOPROPHYLAXIS; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; MITOSIS INHIBITION; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; UPREGULATION;

ABERRANT CRYPT FOCI; ACF; ANALYSIS OF VARIANCE; ANOVA; AOM; AZOXYMETHANE; CARBOXYL METHYL CELLULOSE; CMC; COLON CANCER; COLORECTAL CANCER; CRC; H&E; HEMATOXYLIN AND EOSIN; MCC-555; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; PPAR; PPAR LIGAND; TDT; TDT-MEDIATED DEOXYURIDINE TRIPHOSPHATE NICK-END LABELING; TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE; TUNEL;

ABERRANT CRYPT FOCI; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AZOXYMETHANE; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MICE; MICE, INBRED STRAINS; MITOSIS; MUCIN-2; PPAR GAMMA; THIAZOLIDINEDIONES;

MUS;

EID: 84880036812     PISSN: 09402993     EISSN: 16181433     Source Type: Journal    
DOI: 10.1016/j.etp.2013.01.005     Document Type: Article

References (38)

1. Araki Y., Mukaisyo K., Sugihara H., Fujiyama Y., Hattori T. Increased apoptosis and decreased proliferation of colonic epithelium in dextran sulfate sodium-induced colitis in mice. Oncology Reports 2010, 24:869-874.
2. Asano N., Kuno T., Hirose Y., Yamada Y., Yoshida K., Tomita H., et al. Preventive effects of a flavonoid myricitrin on the formation of azoxymethane-induced premalignant lesions in colons of rats. Asian Pacific Journal of Allergy and Immunology 2007, 1:73-76.
3. Baek S.J., Kim J., Nixon J.B., DiAugustine R.P., Eling T.E. Expression of NAG-1, a transforming growth factor-β superfamily member, by troglitazone requires the early growth response gene EGR-1. Journal of Biological Chemistry 2004, 279:6883-6892.
4. Baek S.J., Okazaki R., Lee S.H., Martinez J., Kim J.S., Yamaguchi K., et al. Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology 2006, 131:1553-1560.
5. Baek S.J., Wilson L.C., Hsi L.C., Eling T.E. Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. Journal of Biological Chemistry 2003, 8:5845-5853.
6. Bird R.P. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Letters 1987, 37:147-151.
7. Blache P., van de Wetering M., Duluc I., Domon C., Berta P., Freund J.-N., et al. SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. Journal of Biological Chemistry 2004, 166:37-47.
8. Carter J.W., Lancaster H.K., Hardman W.E., Cameron I.L. Distribution of intestine-associated lymphoid tissue, aberrant crypt foci, and tumors in the large bowel of 1,2-dimethylhydrazine-treated mice. Cancer Research 1994, 54:4304-4307.
9. Chintharlapalli S., Papineni S., Jutooru I., McAlees A., Safe S. Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator-activated receptor γ agonists in colon cancer cells. Molecular Cancer Therapeutics 2007, 6:1588-1598.
10. Dionne S., Levy E., Levesque D., Seidman E.G. PPARγ ligand 15-deoxy-delta 12,14-prostaglandin j2 sensitizes human colon carcinoma cells to TWEAK-induced apoptosis. Anticancer Research 2010, 30:157-166.
11. Dirisina R., Katzman R.B., Goretsky T., Managlia E., Mittal N., Williams D.B., et al. p53 and PUMA independently regulate apoptosis of intestinal epithelial cells in patients and mice with colitis. Gastroenterology 2011, 141:1036-1045.
12. Elstner E., Müller C., Koshizuka K., Williamson E.A., Park D., Asou H., et al. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:8806-8811.
13. Garcia-Albeniz X., Chan A.T. Aspirin for the prevention of colorectal cancer. Best Practice & Research Clinical Endocrinology & Metabolism 2011, 25:461-472.
14. Kohno H., Suzuki R., Curini M., Epifano F., Maltese F., Gonzales S.P., et al. Dietary administration with prenyloxycoumarins, auraptene and collinin, inhibits colitis-related colon carcinogenesis in mice. International Journal of Cancer 2006, 118:2936-2942.
15. Kopelovich L., Fay J.R., Glazer R.I., Crowell J.A. Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents. Molecular Cancer Therapeutics 2002, 5:357-363.
16. Kumagai T., Ikezoe T., Gui D., O'Kelly J., Tong X.-J., Cohen F.J., et al. RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-γ ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/x-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by arsenic trioxide. Clinical Cancer Research 2004, 10:1508-1520.
17. Motomura W., Okumura T., Takahashi N., Obara T., Kohgo Y. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer Research 2000, 5558-5564.
18. Naumov G.N., Akslen L.A., Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 2006, 5:1779-1787.
19. Ollberding N., Wilkens L., Henderson B., Kolonel L., Marchand L.L. Meat consumption, heterocyclic amines and colorectal cancer risk: the multiethnic cohort study. International Journal of Cancer 2012.
20. Ookawa K., Kudo T., Aizawa S., Saito H., Tsuchida S. Transcriptional activation of the MUC2 gene by p53. Journal of Biological Chemistry 2002, 277:48270-48275.
21. Papanikolaou A., Wang Q.-S., Papanikolaou D., Whiteley H.E., Rosenberg D.W. Sequential and morphological analyses of aberrant crypt foci formation in mice of differing susceptibility to azoxymethane-induced colon carcinogenesis. Carcinogenesis 2000, 21:1567-1572.
22. Papi A., Rocchi P., Ferreri A.M., Orlandi M. RXRγ and PPARγ ligands in combination to inhibit proliferation and invasiveness in colon cancer cells. Cancer Letters 2010, 297:65-74.
23. Patel B.B., Yu Y., Du J., Rishi A.K., Sarkar F.H., Tarca A.L., et al. Schlafen 3, a novel gene, regulates colonic mucosal growth during aging. American Journal of Physiology. Gastrointestinal and Liver Physiology 2009, 296. G955- G62.
24. Ravichandran K., Velmurugan B., Gu M., Singh R.P., Agarwal R. Inhibitory effect of silibinin against azoxymethane-induced colon tumorigenesis in A/J mice. Clinical Cancer Research 2010, 16:4595-4606.
25. Reginato M.J., Bailey S.T., Krakow S.L., Minami C., Ishii S., Tanaka H., et al. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties. Journal of Biological Chemistry 1998, 273:32679-32684.
26. Rumi M.A.K., Ishihara S., Kadowaki Y., Ortega-Cava C.F., Kazumori H., Kawashima K., et al. Peroxisome proliferator-activated receptor γ-dependent and -independent growth inhibition of gastrointestinal tumour cells. Genes to Cells 2004, 9:1113-1123.
27. Schmelz E.M., Xu H., Sengupta R., Du J., Banerjee S., Sarkar F.H., et al. Regression of early and intermediate stages of colon cancer by targeting multiple members of the EGFR family with EGFR-related protein. Cancer Research 2007, 67:5389-5396.
28. Stevens R.G., Swede H., Heinen C.D., Jablonski M., Grupka M., Ross B., et al. Aberrant crypt foci in patients with a positive family history of sporadic colorectal cancer. Cancer Letters 2007, 248:262-268.
29. Suzuki R., Kohno H., Sugie S., Tanaka T. Sequential observations on the occurrence of preneoplastic and neoplastic lesions in mouse colon treated with azoxymethane and dextran sodium sulfate. Cancer Science 2004, 95:721-727.
30. Takahashi M., Wakabayashi K. Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents. Cancer Science 2004, 95:475-480.
31. Tammali R., Reddy A.B.M., Ramana K.V., Petrash J.M., Srivastava S.K. Aldose reductase deficiency in mice prevents azoxymethane-induced colonic preneoplastic aberrant crypt foci formation. Carcinogenesis 2009, 30:799-807.
32. Tsubouchi Y., Sano H., Kawahito Y., Mukai S., Yamada R., Kohno M., et al. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonists through induction of apoptosis. Biochemical and Biophysical Research Communications 2000, 270:400-405.
33. Turturro F., Friday E., Fowler R., Surie D., Welbourne T. Troglitazone acts on cellular pH and DNA synthesis through a peroxisome proliferator-activated receptor γ-independent mechanism in breast cancer-derived cell lines. Clinical Cancer Research 2004, 10:7022-7030.
34. Velcich A., Yang W., Heyer J., Fragale A., Nicholas C., Viani S., et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 2002, 5560:1726-1729.
35. Velmurugan B., Singh R.P., Tyagi A., Agarwal R. Inhibition of azoxymethane-induced colonic aberrant crypt foci formation by silibinin in male fisher 344 rats. Cancer Prevention Research (Phila) 2008, 1:376-384.
36. Volate S.R., Davenport D.M., Muga S.J., Wargovich M.J. Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin). Carcinogenesis 2005, 26:1450-1456.
37. Yamaguchi K., Cekanova M., McEntee M.F., Yoon J., Fischer S.M., Renes I.B., et al. Peroxisome proliferator-activated receptor ligand MCC-555 suppresses intestinal polyps in ApcMin/+ mice via extracellular signal-regulated kinase and peroxisome proliferator-activated receptor-dependent pathways. Molecular Cancer Therapeutics 2008, 7:2779-2787.
38. Yamaguchi K., Lee S.H., Eling T.E., Baek S.J. A novel peroxisome proliferator-activated receptor gamma ligand, MCC-555, induces apoptosis via posttranscriptional regulation of NAG-1 in colorectal cancer cells. Molecular Cancer Therapeutics 2006, 1352-1361.